Clinical trial
Trial Comparing 3 and 4 Week Regimen of Gemcitabine and Cisplatin in Patients…
NCT00489996 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00489996 |
|---|---|
| Title | Trial Comparing 3 and 4 Week Regimen of Gemcitabine and Cisplatin in Patients With Lung Cancer |
| Official title | A Multicenter, Randomized Trial Comparing a Combined Gemcitabine and Cisplatin 3-Week Regimen With a 4-Week Regimen in Non-Small Cell Lung Cancer Patients |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Non-Small Cell Lung Cancer |
| Intervention type | Drug |
| Interventions | gemcitabine, cisplatin |
| Enrollment | 100 |
| Start date | Jan 1, 2003 |
| Completion | Jun 1, 2005 |
| First posted | Jun 22, 2007 |
| Last update posted | Jun 22, 2007 |
| Countries | China |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: